Literature DB >> 32234258

Association between sarcoidosis and cardiovascular comorbidity: A systematic review and meta-analysis.

Abdalla Reda Mahmoud1, Abdullah Dahy1, Mahmoud Dibas2, Alzhraa Salah Abbas1, Sherief Ghozy3, Amr Ehab El-Qushayri1.   

Abstract

BACKGROUND: Sarcoidosis with cardiovascular involvement is critical and is associated with morbidity and mortality of the affected patients, if not properly managed. In this systematic review and meta-analysis, we aimed to review the available literature to find the prevalence of cardiovascular comorbidities and their association with sarcoidosis.
METHODS: An electronic search was conducted through nine databases for articles reporting cardiovascular comorbidities in sarcoidosis patients. We assessed the quality of each included article using the National Institute of Health quality assessment tool (NIH), while meta-analysis was used to pool the results.
RESULTS: Out of 2208 reports screened, we included 14 studies. The most common cardiovascular comorbidities were hypertension 28.8%, heart failure 9.3% and non-specified arrhythmia 8.1%. There were significant association between sarcoidosis and heart failure and hypertension rather than controls (OR = 2.10, 95%CI (1.65 - 2.69), p < 0.01) and (OR = 1.27, 95%CI (1.02 - 1.59), p = 0.036), respectively. However, we found no association between sarcoidosis and cerebrovascular disease, ischemic heart disease and ventricular tachycardia (p > 0.05).
CONCLUSION: Sarcoidosis is associated with certain types of cardiovascular comorbidities. Timely diagnosis and aggressive management in this population are needed to minimize the hazards associated with the disease.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular; Sarcoidosis; Systematic review

Year:  2020        PMID: 32234258     DOI: 10.1016/j.hrtlng.2020.03.013

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  5 in total

1.  Metabolic syndrome may be more frequent in treatment-naive sarcoidosis patients.

Authors:  Arzu Cennet Işık; Murat Kavas; Mehmet Engin Tezcan
Journal:  Z Rheumatol       Date:  2022-04-26       Impact factor: 1.372

2.  Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis.

Authors:  Vikash Jaiswal; Song Peng Ang; Zouina Sarfraz; Swatika Butey; Harshwardhan Vinod Khandait; David Song; Jia Ee Chia; Dipansha Maroo; Muhammad Hanif; Mohammed Ghanim; Raja Chand; Monodeep Biswas
Journal:  Int J Cardiol Heart Vasc       Date:  2022-06-29

3.  The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis.

Authors:  Wei-Wei Wang; Wei-Qi Wang; Shan-Shan Wang; Lei Pan
Journal:  Ann Transl Med       Date:  2022-05

4.  Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.

Authors:  Allan Lawrie; Neil Hamilton; Steven Wood; Fernando Exposto; Ruvimbo Muzwidzwa; Louise Raiteri; Amélie Beaudet; Audrey Muller; Rafael Sauter; Nadia Pillai; David G Kiely
Journal:  Pulm Circ       Date:  2022-09-30       Impact factor: 2.886

5.  The Interrelationship between Sarcoidosis and Atherosclerosis-Complex Yet Rational.

Authors:  Sara Hoss; Tzlil Grinberg; Alon Eisen
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.